We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study
Read MoreHide Full Article
Mirati Therapeutics, Inc. announced positive data from a cohort of the phase I/II KRYSTAL–1 study evaluating its leading KRAS inhibitor adagrasib in patients with heavily pretreated colorectal cancer (“CRC”).
The cohort from the study evaluated adagrasib (600mg BID) in two arms, as a monotherapy and in a combination with Eli Lilly’s (LLY - Free Report) Erbitux (cetuximab). In both arms of the study, adagrasib achieved significant clinical activity and broad disease control in patients with KRAS G12C-Mutated CRC.
In the year so far, Mirati’s stock price has plunged 20.7% against the industry’s 0.9% rise.
Image Source: Zacks Investment Research
In the monotherapy arm, the investigator-assessed response rate (“RR”) was 22% and disease control rate (“DCR”) was 87% (as of May 25, 2021). In the combination arm, the investigator-assessed RR was 43% and DCR was 100% (as of Jul 9, 2021).
Data from the KRYSTAL–1 study also demonstrated that the therapy was well tolerated among the participants in both arms of the cohort. The data were presented at the European Society for Medical Oncology Congress (ESMO) 2021.
Mirati has completed enrolment in a phase II potentially registration-enabling monotherapy cohort of adagrasib for treating patients with at least second-line non-small cell lung cancer (“NSCLC”) with KRAS G12C mutation. Mirati anticipates filing a new drug application for the accelerated approval of adagrasib in fourth-quarter 2021 to treat the given indication.
Enrolment is also ongoing in other key cohorts of the above study, which is evaluating adagrasib plus Merck’s (MRK - Free Report) Keytruda for first-line NSCLC and adagrasib plus Erbitux for second-line CRC.
Mirati is also conducting the phase III KRYSTAL-10 study, which is evaluating adagrasib plus Erbitux with a standard of care chemotherapy in patients with second-line CRC.
Please note that tumors characterized by KRAS mutations are commonly associated with poor prognosis and resistance to therapy. KRAS mutations are extremely difficult to directly inhibit. Adagrasib is designed to directly inhibit KRAS G12C mutations and if approved, it can open a market with significant unmet needs.
Amgen’s (AMGN - Free Report) Lumakras, a KRAS inhibitor, is also being evaluated in a phase II monotherapy study in advanced CRC patients. In May 2021, Lumakras became the first KRAS inhibitor to be approved in the United States for treating KRAS G12C-mutated locally advanced or metastatic NSCLC.
Image: Bigstock
Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study
Mirati Therapeutics, Inc. announced positive data from a cohort of the phase I/II KRYSTAL–1 study evaluating its leading KRAS inhibitor adagrasib in patients with heavily pretreated colorectal cancer (“CRC”).
The cohort from the study evaluated adagrasib (600mg BID) in two arms, as a monotherapy and in a combination with Eli Lilly’s (LLY - Free Report) Erbitux (cetuximab). In both arms of the study, adagrasib achieved significant clinical activity and broad disease control in patients with KRAS G12C-Mutated CRC.
In the year so far, Mirati’s stock price has plunged 20.7% against the industry’s 0.9% rise.
Image Source: Zacks Investment Research
In the monotherapy arm, the investigator-assessed response rate (“RR”) was 22% and disease control rate (“DCR”) was 87% (as of May 25, 2021). In the combination arm, the investigator-assessed RR was 43% and DCR was 100% (as of Jul 9, 2021).
Data from the KRYSTAL–1 study also demonstrated that the therapy was well tolerated among the participants in both arms of the cohort. The data were presented at the European Society for Medical Oncology Congress (ESMO) 2021.
Mirati has completed enrolment in a phase II potentially registration-enabling monotherapy cohort of adagrasib for treating patients with at least second-line non-small cell lung cancer (“NSCLC”) with KRAS G12C mutation. Mirati anticipates filing a new drug application for the accelerated approval of adagrasib in fourth-quarter 2021 to treat the given indication.
Enrolment is also ongoing in other key cohorts of the above study, which is evaluating adagrasib plus Merck’s (MRK - Free Report) Keytruda for first-line NSCLC and adagrasib plus Erbitux for second-line CRC.
Mirati is also conducting the phase III KRYSTAL-10 study, which is evaluating adagrasib plus Erbitux with a standard of care chemotherapy in patients with second-line CRC.
Please note that tumors characterized by KRAS mutations are commonly associated with poor prognosis and resistance to therapy. KRAS mutations are extremely difficult to directly inhibit. Adagrasib is designed to directly inhibit KRAS G12C mutations and if approved, it can open a market with significant unmet needs.
Amgen’s (AMGN - Free Report) Lumakras, a KRAS inhibitor, is also being evaluated in a phase II monotherapy study in advanced CRC patients. In May 2021, Lumakras became the first KRAS inhibitor to be approved in the United States for treating KRAS G12C-mutated locally advanced or metastatic NSCLC.
Mirati Therapeutics, Inc. Price
Mirati Therapeutics, Inc. price | Mirati Therapeutics, Inc. Quote
Zacks Rank
Mirati currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.